Study how acid reflux may affect lung scarring
Part of Digestive system clinical trials.
This trial studies whether reflux (acid moving up toward the throat) plays a role in idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes scarred. It may help doctors understand triggers that could worsen symptoms and guide more targeted care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with IPF (idiopathic pulmonary fibrosis)
- You are between 40 and 95 years old
- You can read, speak, and understand English well enough for study visits
- If you take medicines for reflux or GERD, your dose must be steady for at least 4 weeks before joining
- You are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
This study looks at what factors contribute to worsening lung scarring seen on scans in people with certain lung diseases. Results may help doctors better understand and predict who will worsen over time.
This study looks at what causes familial (inherited) pulmonary fibrosis by studying relatives who are not yet diagnosed with the lung disease. You may help researchers understand risk and early changes in the lungs within families.
This study follows patients with chronic lung scarring (fibrosing interstitial lung disease) who are in the intensive care unit for severe breathing failure. It aims to better understand their condition and care, which may help improve future treatments.
Hear when a new IPF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.